Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?

Ahmed, Rifat Zubair; Rashid, Munazza; Ahmed, Nuzhat; Nadeem, Muhammad; Shamsi, Tahir Sultan

추천

검색

자료유형: 학술저널

저자정보: Ahmed, Rifat Zubair (Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow Transplantation) Rashid, Munazza (Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow Transplantation) Ahmed, Nuzhat (Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow Transplantation) Nadeem, Muhammad (Centre of Excellence in Molecular Medicine, National Institute of Blood Disease and Bone Marrow Transplantation) Shamsi, Tahir Sultan (Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow Transplantation)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제17권 제3호

발행연도: 2016.1

수록면: 923 - 926 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

The classic BCR-ABL1-negative myeloproliferative neoplasm is an operational sub-category of MPNs that includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The JAK2V617F mutation is found in ~ 95% of PV and 50-60% of ET or PMF. In most of the remaining JAK2V617F-negative PV cases, JAK2 exon 12 mutations are present. Amongst the JAK2V617F-negative ET or PMF 5-10% of patients carry mutations in the MPL gene. Prior to 2013, there was no specific molecular marker described in the remaining 30-40% ET and PMF. In December 2013, two research groups independently reported mutations in the gene CALR found specifically in ET (67-71%) and PMF (56-88%) but not in PV. Initially CALR mutations were reported mutually exclusive with JAK2 or MPL. However, co-occurrence of CALR mutations with JAK2V617F has been reported recently in a few MPN cases. Many studies have reported important diagnostic and prognostic significance of CALR mutations in ET and PMF patients and CALR mutation screening has been proposed to be incorporated into WHO diagnostic criteria for MPN. It is suggestive in diagnostic workup of MPN that CALR mutations should not be studied in MPN patients who carry JAK2 or MPL mutations. However JAK2V617F and CALR positive patients might have a different phenotype and clinical course, distinct from the JAK2-positive or CALR-positive subgroups and identification of the true frequency of these patients may be an important factor for defining the prognosis, risk factors and outcomes for MPN patients.

#Calreticulin #essential thrombocythemia #myeloproliferative neoplasms #JAK2V617F

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Ahmed, Rifat Zubair

소속기관 Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow